S&P 500 Futures
(-0.04%) 5 306.00 points
Dow J Futures
(0.00%) 40 145 points
Nasdaq Futures
(-0.05%) 18 494 points
Oil
(1.07%) $82.22
Gas
(-1.16%) $1.698
Gold
(0.89%) $2 232.30
Silver
(0.18%) $24.80
Platinum
(0.23%) $911.75
USD/EUR
(0.38%) $0.927
USD/NOK
(0.62%) $10.84
USD/GBP
(0.18%) $0.793
USD/RUB
(-0.19%) $92.27

Realtime updates for Ono Pharmaceutical Co., [4528.T]

Exchange: JPX Sector: Healthcare Industry: Drug Manufacturers—General
Last Updated28 Mar 2024 @ 02:15

-0.50% ¥ 2 477.00

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 02:15):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors...

Stats
Today's Volume 1.37M
Average Volume 2.09M
Market Cap 1 175.96B
EPS ¥0 ( 2024-01-30 )
Next earnings date ( ¥51.38 ) 2024-05-07
Last Dividend ¥37.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 9.38
ATR14 ¥0.836 (0.03%)

Volume Correlation

Long: -0.31 (neutral)
Short: 0.89 (strong)
Signal:(54.082) Same movement expected

Ono Pharmaceutical Co., Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ono Pharmaceutical Co., Correlation - Currency/Commodity

The country flag 0.69
( moderate )
The country flag 0.50
( weak )
The country flag 0.04
( neutral )
The country flag 0.00
( neutral )
The country flag 0.67
( moderate )
The country flag -0.27
( neutral )

Ono Pharmaceutical Co., Financials

Annual 2022
Revenue: ¥447.19B
Gross Profit: ¥337.13B (75.39 %)
EPS: ¥230.85
Q3 2023
Revenue: ¥131.19B
Gross Profit: ¥100.49B (76.60 %)
EPS: ¥75.77
Q2 2023
Revenue: ¥138.70B
Gross Profit: ¥104.10B (75.06 %)
EPS: ¥88.18
Q1 2023
Revenue: ¥120.02B
Gross Profit: ¥89.85B (74.86 %)
EPS: ¥65.16

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥33.00
(N/A)
¥0
(N/A)
¥37.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.63 - Stable (12.69%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥6.80 2001-03-27
Last Dividend ¥37.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 41 --
Total Paid Out ¥671.50 --
Avg. Dividend % Per Year 0.00% --
Score 4.16 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.63
Div. Directional Score 9.15 --
Next Divdend (Est)
(2024-10-14)
¥0 Estimate 3.61 %
Dividend Stability
0.29 Very Poor
Dividend Score
4.16
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
2813.T Ex Dividend Knight 2024-03-28 Annually 0 0.00%
1515.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
9919.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
8960.T Ex Dividend Knight 2023-11-29 Semi-Annually 0 0.00%
8097.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
7458.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
6728.T Ex Dividend Junior 2024-06-27 Annually 0 0.00%
6099.T Ex Dividend Junior 2023-12-28 Annually 0 0.00%
4829.T Ex Dividend Junior 2024-05-30 Annually 0 0.00%
4058.T Ex Dividend Junior 2023-12-28 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2561.5004.887.31[0 - 0.5]
returnOnAssetsTTM0.1431.2005.236.28[0 - 0.3]
returnOnEquityTTM0.1661.5009.2610.00[0.1 - 1]
payoutRatioTTM0.291-1.0007.09-7.09[0 - 1]
currentRatioTTM3.950.80010.008.00[1 - 3]
quickRatioTTM3.190.80010.008.00[0.8 - 2.5]
cashRatioTTM1.1401.5004.787.17[0.2 - 2]
debtRatioTTM0.00963-1.5009.84-10.00[0 - 0.6]
interestCoverageTTM99.031.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM222.862.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM191.882.0010.0010.00[0 - 20]
debtEquityRatioTTM0.0109-1.5009.96-10.00[0 - 2.5]
grossProfitMarginTTM0.7561.0000.7400.740[0.2 - 0.8]
operatingProfitMarginTTM0.3291.0005.415.41[0.1 - 0.6]
cashFlowToDebtRatioTTM12.351.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.5590.8009.617.69[0.5 - 2]
Total Score12.67

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM9.261.0009.170[1 - 100]
returnOnEquityTTM0.1662.509.5310.00[0.1 - 1.5]
freeCashFlowPerShareTTM191.882.0010.0010.00[0 - 30]
dividendYielPercentageTTM4.711.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM222.862.0010.0010.00[0 - 30]
payoutRatioTTM0.2911.5007.09-7.09[0 - 1]
pegRatioTTM-1.5641.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2131.0007.180[0.1 - 0.5]
Total Score5.63

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators